- Home
- VEL vs KALV Comparison
VEL vs KALV Comparison
Compare VEL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- KALV
- Stock Information
- Founded
- VEL 2004
- KALV N/A
- Country
- VEL United States
- KALV United States
- Employees
- VEL N/A
- KALV N/A
- Industry
- VEL Finance: Consumer Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- KALV Health Care
- Exchange
- VEL Nasdaq
- KALV Nasdaq
- Market Cap
- VEL 602.1M
- KALV 551.2M
- IPO Year
- VEL 2020
- KALV N/A
- Fundamental
- Price
- VEL $18.84
- KALV $10.78
- Analyst Decision
- VEL Strong Buy
- KALV Strong Buy
- Analyst Count
- VEL 3
- KALV 8
- Target Price
- VEL $21.67
- KALV $26.43
- AVG Volume (30 Days)
- VEL 60.1K
- KALV 1.1M
- Earning Date
- VEL 11-06-2025
- KALV 11-11-2025
- Dividend Yield
- VEL N/A
- KALV N/A
- EPS Growth
- VEL 26.95
- KALV N/A
- EPS
- VEL 2.22
- KALV N/A
- Revenue
- VEL $195,592,000.00
- KALV $1,426,000.00
- Revenue This Year
- VEL $3.99
- KALV N/A
- Revenue Next Year
- VEL $29.69
- KALV $234.65
- P/E Ratio
- VEL $8.48
- KALV N/A
- Revenue Growth
- VEL 44.29
- KALV N/A
- 52 Week Low
- VEL $16.12
- KALV $7.30
- 52 Week High
- VEL $20.98
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- VEL 59.89
- KALV 37.93
- Support Level
- VEL $17.74
- KALV $10.86
- Resistance Level
- VEL $18.73
- KALV $11.30
- Average True Range (ATR)
- VEL 0.35
- KALV 0.47
- MACD
- VEL 0.06
- KALV 0.03
- Stochastic Oscillator
- VEL 88.03
- KALV 25.88
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.